Exozymes Inc (EXOZ) Institutional Ownership Tracker (Q2 2026)

EXOZ ranks #10070 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

10 institutions disclose a position in EXOZ, but none treat it as a major bet — even Davidson Kahn Capital Management, LLC, its most concentrated holder, allocates just 0.1% of its own portfolio to it.

UBS Group AG has added to its EXOZ position for two straight quarters, increasing it by $1.7K to reach $1.7K today.

EXOZ reported a net loss of $9.2M in its latest fiscal year.

• Not yet profitable — net loss of $9.2M in the latest fiscal year
• Revenue grew 43.8% year over year
• Net income declined year over year, from -$5.9M to -$9.2M
• Operating cash flow was negative, using $6.5M in cash
• Current ratio of 2.51x — enough short-term assets to cover short-term liabilities
• Liabilities run 321783.50x equity — a highly leveraged balance sheet worth noting